CCR2 and cerebral palsy: These newer CCR2 inhibitors are more suited for clinical application in infants suffered from birth asphyxia or HIE, especially when compounded by chorioamnionitis, which carries a higher risk for cerebral palsy and poor responses to therapeutic hypothermia 1, 2.